title: Monitoring performance of progression assessment criteria for cancer antigen 125 among patients with ovarian cancer compared by computer simulation.
abstract: BACKGROUND
  Cancer antigen 125 (CA125) is used to monitor tumor burden among patients with advanced serous epithelial ovarian cancer. The purpose is to compare the monitoring performance of seven previously proposed criteria.
  
  
  METHODS
  The CA125 assessment criteria were applied to simulated datasets. We investigated the ability to provide information on CA125 increments as well as their robustness against false positive signals.
  
  
  RESULTS
  For baseline concentrations above cut-off, the best performing criterion was based on a confirmed increment ≥2.5-times the nadir concentration. For baseline concentrations below cut-off, the best performing criterion was based on a confirmed increment from ≤ cut-off to >two-times cut-off.
  
  
  CONCLUSIONS
  Computer simulation models may be useful for a preclinical validation of criteria to be investigated in clinical trials.
authors.affiliation: Department of Clinical Biochemistry, North Zealand Hospital Hospital, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Suher Othman
authors.initials: SO
authors.lastname: Abu Hassan
authors.affiliation: Department of Clinical Biochemistry, North Zealand Hospital Hospital, University of Copenhagen, Copenhagen, Denmark.|Norwegian Quality Improvement Primary Care Laboratories (NOKLUS), Section for General Practice, University of Bergen, Bergen, Norway.
authors.forename: Per Hyltoft
authors.initials: PH
authors.lastname: Petersen
authors.affiliation: Department of Clinical Biochemistry, North Zealand Hospital Hospital, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Flemming
authors.initials: F
authors.lastname: Lund
authors.affiliation: Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Dorte L
authors.initials: DL
authors.lastname: Nielsen
authors.affiliation: Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Malgorzata K
authors.initials: MK
authors.lastname: Tuxen
authors.affiliation: Department of Clinical Biochemistry, North Zealand Hospital Hospital, University of Copenhagen, Copenhagen, Denmark.
authors.forename: György
authors.initials: G
authors.lastname: Sölétormos
mesh_terms: D018394:CA-125 Antigen / Q000032:analysis*; D002623:Chemistry Techniques, Analytical; D003198:Computer Simulation; D018450:Disease Progression; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms
chemical_list: D018394:CA-125 Antigen
keywords: CA125; baseline concentration; computer simulations; criteria; false positive results; monitoring; ovarian cancer; progression; steady-state concentration; tumor detection time